KALV
KalVista Pharmaceuticals, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
KalVista Pharmaceuticals (KALV) Stock: Buy, Sell, or Hold?
$27.00
+0.01 (+0.04%)
â˛
5d:
+0.19%
30d:
+1.09%
90d:
+48.03%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (64%)
Quality Score
49/100
Position
FAIR
Forward P/E & Valuation
-9.7x
Next 12M consensus est.
Wall Street Target
$28.60
+5.9% upside
Options IV & Volume
UNKNOWN Vol
UNKNOWN volume confirmation
Support / Resistance
$26.77 / $27.00
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: KALV is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When KALV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: KALV is currently trading at $27.00, which is considered fair based on recent price action.
Technical Outlook: Technically, KALV is in a strong uptrend. The price is currently testing key support at $26.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KALV is in a strong uptrend. The price is currently testing key support at $26.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
49/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
64.2%
Trading Range & Key Levels
Support Level
$26.77
Resistance Level
$27.00
Current Trend
Strong Uptrend
Technical data as of
Jun 10, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- NEUTRAL: Near Wall St target ($28.60)
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-9.68
Wall Street Target
$28.60
(+5.9%)
Revenue Growth (YoY)
30.7%
Profit Margin
-118.7%
Share KALV Analysis
Share this live KALV analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (KALV)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Apr 30, 2026
Daily AI digest
AI Retail Discussion Summary:
Shares of KalVista Pharmaceuticals surged on Wednesday following a 1.9 billion takeover offer from Chiesi Group, which aims to expand its rare disease portfolio.
Key Retail Themes:
M&A activity
Rare disease portfolio expansion
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 3:25 AM ET
Data refreshes hourly during market hours. Next update: 4:25 AM
Data refreshes hourly during market hours. Next update: 4:25 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KALV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
28 analysts |
$91 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 52 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$107 | 33 SELL |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 43 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive KALV Research Pages
